Neither BRCA1 nor BRCA2 is universally worse. Each mutation carries a distinct risk profile, and which one hits harder depends on the specific cancer type. BRCA1 brings higher risks for breast and ovarian cancer and tends to strike earlier in life. BRCA2 carries a broader range of associated cancers, including significantly elevated prostate cancer risk in men, and is linked to more aggressive forms of certain cancers. The practical differences between the two matter for screening timelines, preventive surgery decisions, and treatment options.
Breast Cancer Risk: BRCA1 Is Higher
BRCA1 carriers face a 44% to 78% chance of developing breast cancer by age 70. For BRCA2 carriers, that range is 31% to 56%. Both are dramatically higher than the roughly 13% lifetime risk in the general population, but BRCA1 consistently lands at the top.
The type of breast cancer also differs. BRCA1 mutations are strongly associated with triple-negative breast cancer, a subtype that lacks three common receptors used to target treatment. This makes BRCA1-related breast cancers harder to treat with hormone-blocking therapies. BRCA2-associated breast cancers more often express hormone receptors, which opens the door to a wider range of targeted treatments.
Ovarian Cancer Risk: BRCA1 Is Much Higher
This is one of the starkest differences between the two mutations. Women with a BRCA1 mutation have a 39% to 58% lifetime risk of developing ovarian cancer (a category that includes fallopian tube and primary peritoneal cancers). For BRCA2 carriers, the risk is 13% to 29%. Both are far above the 1.1% risk in the general population, but BRCA1 carriers face roughly double the ovarian cancer threat.
This gap is the main reason clinical guidelines recommend different timelines for preventive surgery. NCCN guidelines recommend that BRCA1 carriers consider risk-reducing removal of the ovaries and fallopian tubes between ages 35 and 40, after completing childbearing. For BRCA2 carriers, that window shifts to ages 40 to 45, reflecting the somewhat lower and later-onset ovarian cancer risk.
Age of Onset: BRCA1 Cancers Appear Earlier
BRCA1 carriers tend to develop cancer at younger ages. In one study tracking generational patterns, the mean age at cancer onset for BRCA1 carriers was around 40 to 46 years depending on the generation studied. For BRCA2 carriers, the mean age at onset ranged from about 44 to 54 years. That gap of several years matters for screening decisions. If you carry a BRCA1 mutation, your doctors will typically recommend starting breast MRIs and mammograms in your mid-20s to early 30s, earlier than for many BRCA2 carriers.
Prostate Cancer Risk: BRCA2 Is Significantly Higher
For men, BRCA2 is the more concerning mutation. A prospective study published in European Urology found that male BRCA2 carriers had a 60% cumulative risk of prostate cancer by age 85, compared to 29% for BRCA1 carriers. By age 75, the numbers were 27% for BRCA2 and 21% for BRCA1. BRCA2-associated prostate cancers also tend to be more aggressive, presenting at higher grades and more advanced stages.
Male breast cancer, while rare overall, is also more closely associated with BRCA2. In one large cohort, 35 cases of male breast cancer occurred among BRCA2 carriers compared to just 4 among BRCA1 carriers.
Pancreatic Cancer and Melanoma: BRCA2 Edges Higher
BRCA2 carries a slightly higher risk of pancreatic cancer. From age 40 to 80, the cumulative incidence is approximately 3% for BRCA2 carriers and 2% for BRCA1 carriers. While those percentages sound small, they represent a meaningful increase over the general population’s roughly 1.5% lifetime risk, and pancreatic cancer has one of the lowest survival rates of any cancer type.
BRCA2 is also linked to an elevated melanoma risk. The largest study on this found that BRCA2 carriers were about 2.5 times more likely to develop melanoma than the general population. The connection between BRCA1 and melanoma is less established.
Treatment Response Differences
Both BRCA1 and BRCA2 mutations make cancer cells vulnerable to a class of targeted drugs that exploit defects in DNA repair. These drugs are approved for several BRCA-related cancers, including breast, ovarian, pancreatic, and prostate cancers. However, the two mutations don’t respond equally across all cancer types.
In advanced prostate cancer, BRCA2-altered tumors respond significantly better to these targeted treatments. One study found that 63% of men with BRCA2-altered prostate cancer achieved a meaningful treatment response, compared to just 23% of those with BRCA1 alterations. Similar trends appeared across multiple clinical trials. For breast and ovarian cancers, both mutations generally respond well, though the data is more balanced between the two.
Survival Rates Are Similar for Breast Cancer
Despite the differences in risk and tumor biology, long-term survival for breast cancer doesn’t clearly favor one mutation over the other. A study published in the New England Journal of Medicine evaluated 10-year survival in a national cohort and found that the adjusted risk of dying from breast cancer was not significantly different between BRCA1 carriers, BRCA2 carriers, and women without either mutation. The more aggressive biology of BRCA1-related tumors appears to be offset by their sensitivity to certain chemotherapy regimens.
Which One Should You Worry About More
If you’re a woman, BRCA1 generally poses the greater overall cancer threat. It carries higher breast and ovarian cancer risks, hits earlier in life, and produces tumor types that are harder to treat with hormone therapies. The earlier recommended timeline for preventive surgery reflects this urgency.
If you’re a man, BRCA2 is the more dangerous mutation. The prostate cancer risk is substantially higher and the cancers tend to be more aggressive. BRCA2 also casts a wider net across cancer types, with elevated risks for pancreatic cancer and melanoma on top of the breast and prostate risks.
Neither mutation is benign, and both warrant aggressive screening and serious conversations about preventive options. The specific variant you carry, your family history, and your sex all shape what “worse” actually means for your individual situation. A genetic counselor can map your specific mutation to a personalized risk profile and screening plan.